In this subset, MEK inhibitors or dual inhibitors that show strong synergy with MEK inhibition “i.e., cetuximab” could be effective for preventing and/or overcoming primary resistance to cetuximab in CRC patients as recently reported in preclinical studies [34, 35]. Here, MAP2K7 is linked to colorectal carcinoma.